Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Pancreatin Added to Standard Antihyperglycemic Therapy on Metabolic Control in Patients With Type 2 Diabetes

NCT07852988 is registered in ClinicalTrials.gov with Silesian Centre for Heart Diseases as lead sponsor.

NCT NCT07852988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07852988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Pancreatin Added to Standard Antihyperglycemic Therapy on Metabolic Control in Patients With Type 2 Diabetes
Lead sponsor
Silesian Centre for Heart Diseases
Phase
Phase 4
Overall status
Recruiting
Start date
August 1, 2026
Completion date
December 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes (t2dm)